PCSA Processa Pharmaceuticals, Inc. Insider Trading

CFO Russell Skibsted buys 2,190 shares amid coordinated insider buying cluster; stock near 52-week lows.

Processa Pharmaceuticals' CFO Russell Skibsted is buying shares at depressed valuations—the stock is trading well below its annual highs after significant declines over recent months. What makes this noteworthy is that Skibsted's purchase is part of a broader cluster of three insiders buying within a two-week window, suggesting coordinated confidence rather than isolated portfolio activity. This is noteworthy given the company's challenged fundamentals: Processa is unprofitable with sharply declining revenues, and the CFO's purchase of over half his existing holdings represents a meaningful personal commitment at a time when the company needs to demonstrate operational stability. The question for investors is whether this cluster reflects insiders genuinely believing the stock is oversold at current levels, or whether they're simply averaging down in a struggling biotech.

Chief Strategy Officer at struggling biotech buys shares near 52-week lows amid severe revenue decline.

Lin Patrick, the Chief Business-Strategy Officer at Processa Pharmaceuticals, purchased over 1,500 shares at heavily depressed levels, adding roughly a third to his existing holdings. This is noteworthy timing: the stock is trading well below its recent highs after declining sharply, and the company's fundamentals show severe distress with collapsing revenue and substantial losses. An officer's purchase at depressed valuations could signal either genuine conviction that the market has oversold the company or a forced move to demonstrate confidence during a difficult period. What matters most is whether Patrick's insider knowledge—given his strategy role—suggests the company has stabilized or has genuine catalysts ahead. Without visibility into recent developments, this purchase at depressed levels could be either a courageous contrarian bet or a hollow confidence-building gesture amid ongoing deterioration.

CAO Guy Wendy buys 1,748 shares of struggling biotech PCSA at market lows, adding to holdings amid deep losses.

Chief Administrative Officer Guy Wendy purchased nearly 1,750 shares of Processa Pharmaceuticals at current market levels, representing a meaningful increase to his holdings and signaling confidence in the stock's long-term value. This is noteworthy because the purchase occurs while the company is unprofitable with substantial operating losses and minimal revenue, fundamentals that have deteriorated sharply year-over-year. The stock is trading well below its recent highs, suggesting Wendy sees asymmetric risk-reward at depressed valuations. As a C-suite officer with direct insight into company operations and strategy, his decision to deploy personal capital during a period of financial stress—rather than waiting for turnaround proof—suggests conviction that the business trajectory or assets have value not yet reflected in the market price.